The Role of Capecitabine in the Management of Tumors of the Digestive System

被引：7
作者：
Gennatas, Constantine [1 ]
Michalaki, Vasiliki [1 ]
Gennatas, Spyridon [2 ]
机构：
[1] Arete Hosp, Oncol Clin, Dept Surg, Athens, Greece
[2] Leicester Royal Infirm, Dept Cardiovasc Sci, Leicester, Leics, England
来源：
REVIEWS ON RECENT CLINICAL TRIALS | 2009年 / 4卷 / 01期
关键词：
Capecitabine; esophageal cancer; gastric cancer; gastroesophageal cancer; colorectal cancer; hepatic cancer; biliary tract cancer; gallbladder cancer; pancreatic cancer;
D O I：
10.2174/157488709787047576
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Capecitabine has been developed as a prodrug of FU, with the goal of improving tolerability and intratumor drug concentration through tumor-specific conversion to the active drug. The purpose of this article is to review the available information on capecitabine with respect to clinical efficacy for tumors of the digestive tract, adverse-effect profile, documented drug interactions, dosage and administration, and future directions of ongoing research. Relevant English-language literature was identified through searches of NCI, PubMed, ASCO. org and ESMO, ECCO meetings proceedings.
引用
收藏
页码：1 / 11
页数：11
相关论文
共 74 条
  • [61] Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial
    Scheithauer, W
    McKendrick, J
    Begbie, S
    Borner, M
    Burns, WI
    Burris, HA
    Cassidy, J
    Jodrell, D
    Koralewski, P
    Levine, EL
    Marschner, N
    Maroun, J
    Garcia-Alfonso, P
    Tujakowski, J
    Van Hazel, G
    Wong, A
    Zaluski, J
    Twelves, C
    [J]. ANNALS OF ONCOLOGY, 2003, 14 (12) : 1735 - 1743
  • [62] Schmiegel W, 2007, 43 AM SOC CLIN ONC A
  • [63] Single agent fluorouracil for-first-line treatment of advanced colorectal cancer as standard?
    Schmoll, Hans-Joachim
    Sargent, Daniel
    [J]. LANCET, 2007, 370 (9582) : 105 - 107
  • [64] Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients
    Schüller, J
    Cassidy, J
    Dumont, E
    Roos, B
    Durston, S
    Banken, L
    Utoh, M
    Mori, K
    Weidekamm, E
    Reigner, B
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (04) : 291 - 297
  • [65] Shinohara ET, 2008, 2008 AM SOC CLIN ONC
  • [66] Biological therapy update in colorectal cancer
    Sorscher, Steven M.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2007, 7 (04) : 509 - 519
  • [67] Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF
    Sumpter, K
    Harper-Wynne, C
    Cunningham, D
    Rao, S
    Tebbutt, N
    Norman, AR
    Ward, C
    Iveson, T
    Nicolson, M
    Hickish, T
    Hill, M
    Oates, J
    [J]. BRITISH JOURNAL OF CANCER, 2005, 92 (11) : 1976 - 1983
  • [68] Rapid resolution of liver metastasis from cholangiocarcinoma after bevacizumab with cisplatin and high-dose fluorouracil plus leucovorin
    Tai, CJ
    Chiou, HY
    Wu, CH
    Pan, S
    Liu, JD
    [J]. ONKOLOGIE, 2006, 29 (04): : 179 - 180
  • [69] Capecitabine as adjuvant treatment for stage III colon cancer
    Twelves, C
    Wong, A
    Nowacki, MP
    Abt, M
    Burris, H
    Carrato, A
    Cassidy, J
    Cervantes, A
    Fagerberg, J
    Georgoulias, V
    Husseini, F
    Jodrell, D
    Koralewski, P
    Kröning, H
    Maroun, J
    Marschner, N
    McKendrick, J
    Pawlicki, M
    Rosso, R
    Schüller, J
    Seitz, JF
    Stabuc, B
    Tujakowski, J
    Van Hazel, G
    Zaluski, J
    Scheithauer, W
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (26) : 2696 - 2704
  • [70] Capecitabine (Xeloda™) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma
    Twelves, C
    Boyer, M
    Findlay, M
    Cassidy, J
    Weitzel, C
    Baker, C
    Osterwalder, B
    Jamieson, C
    Hieke, K
    [J]. EUROPEAN JOURNAL OF CANCER, 2001, 37 (05) : 597 - 604
12345678